Among the cohort of 333 patients that underwent treatment with anti-PD-1 or anti-PD-L1 antibody therapy, 115 fatalities were ascribed to pneumonia, accounting for 35% of the cases. The gene discussed is PDCD1; the disease is susceptibility to pneumonia measurement.